UBS Group
PRLD icon

UBS Group’s Prelude Therapeutics PRLD Stock Holding History

UBS Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
318,797
+254,292
+394% +$1.11M ﹤0.01% 5253
2026
Q1 		$221K Buy
64,505
+62,648
+3,374% +$164K ﹤0.01% 6584
2025
Q4 		$5.38K Sell
1,857
-2,314
-55% -$3.9K ﹤0.01% 8690
2025
Q3 		$6.01K Sell
4,171
-100,033
-96% -$100K ﹤0.01% 8810
2025
Q2 		$84.3K Buy
104,204
+8,048
+8% +$6.97K ﹤0.01% 7375
2025
Q1 		$73.8K Buy
96,156
+28,766
+43% +$26.8K ﹤0.01% 7288
2024
Q4 		$85.9K Buy
67,390
+60,374
+861% +$80.1K ﹤0.01% 6968
2024
Q3 		$14.5K Sell
7,016
-3,918
-36% -$18.1K ﹤0.01% 7543
2024
Q2 		$41.7K Sell
10,934
-4,721
-30% -$19.2K ﹤0.01% 6833
2024
Q1 		$74.2K Sell
15,655
-4,218
-21% -$16.4K ﹤0.01% 6344
2023
Q4 		$84.9K Buy
19,873
+12,465
+168% +$37.9K ﹤0.01% 6274
2023
Q3 		$22.9K Buy
7,408
+516
+7% +$1.94K ﹤0.01% 6739
2023
Q2 		$31K Buy
6,892
+5,912
+603% +$35.3K ﹤0.01% 6702
2023
Q1 		$5.59K Sell
980
-57
-5% -$348 ﹤0.01% 8018
2022
Q4 		$6.26K Buy
1,037
+969
+1,425% +$6.21K ﹤0.01% 9059
2022
Q3 		$0 Sell
68
-2,638
-97% -$17.8K ﹤0.01% 10794
2022
Q2 		$14K Buy
2,706
+2,523
+1,379% +$12.8K ﹤0.01% 7415
2022
Q1 		$1K Sell
183
-1,755
-91% -$16.1K ﹤0.01% 9903
2021
Q4 		$23K Sell
1,938
-35,063
-95% -$570K ﹤0.01% 7682
2021
Q3 		$1.16M Buy
37,001
+29,433
+389% +$953K ﹤0.01% 4066
2021
Q2 		$216K Sell
7,568
-14,768
-66% -$526K ﹤0.01% 5285
2021
Q1 		$968K Buy
22,336
+19,755
+765% +$1.31M ﹤0.01% 4283
2020
Q4 		$185K Buy
2,581
+1,158
+81% +$57.6K ﹤0.01% 5284
2020
Q3 		$43K Buy
+1,423
New +$40.2K ﹤0.01% 5755

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

UBS Group's PRLD Position: Q2 2026 in Review

UBS Group increased its Prelude Therapeutics (PRLD) stake by 394% in Q2 2026, buying an estimated $1.11M and bringing the position to 318,797 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #5253.

UBS Group first reported a position in PRLD in Q3 2020 and has held it in 24 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • UBS Group held 318,797 shares of Prelude Therapeutics worth $1.7M as of Q2 2026.
  • UBS Group bought 254,292 Prelude Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Prelude Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5253 holding.
  • UBS Group first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.